Have a feature idea you'd love to see implemented?
Let us know!
CDMO Avid Bioservices Inc
Price (delayed)
$10.21
Market cap
$651.35M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.28
Enterprise value
$823.93M
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biopharmaceutical drug substances derived from mammalian cell culture. The company provides a
Highlights
CDMO's gross profit has dropped by 66% year-on-year but it is up by 22% since the previous quarter
Avid Bioservices's gross margin has plunged by 64% YoY but it has increased by 21% from the previous quarter
Avid Bioservices's equity has shrunk by 69% YoY and by 3.7% QoQ
The company's debt rose by 9% YoY
Key stats
What are the main financial stats of CDMO
Market
Valuations
Earnings
Shares outstanding
63.8M
Market cap
$651.35M
Enterprise value
$823.93M
Price to book (P/B)
11.07
Price to sales (P/S)
4.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.79
Revenue
$142.36M
EBIT
-$23.77M
EBITDA
-$12.48M
Free cash flow
-$11.45M
Per share
Balance sheet
Liquidity
EPS
-$2.28
Free cash flow per share
-$0.18
Book value per share
$0.92
Revenue per share
$2.24
TBVPS
$5.26
Total assets
$334.64M
Total liabilities
$276.01M
Debt
$205.96M
Equity
$58.64M
Working capital
$32.54M
Debt to equity
3.51
Current ratio
1.46
Quick ratio
0.76
Net debt/EBITDA
-13.83
Margins
Efficiency
Dividend
EBITDA margin
-8.8%
Gross margin
6.3%
Net margin
-101.3%
Operating margin
-13.3%
Return on assets
-36.5%
Return on equity
-119.4%
Return on invested capital
-5.7%
Return on capital employed
-9%
Return on sales
-16.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CDMO stock price
How has the Avid Bioservices stock price performed over time
Intraday
-1.45%
1 week
0.59%
1 month
-12.06%
1 year
44.62%
YTD
57.08%
QTD
-10.28%
Financial performance
How have Avid Bioservices's revenue and profit performed over time
Revenue
$142.36M
Gross profit
$8.93M
Operating income
-$18.97M
Net income
-$144.17M
Gross margin
6.3%
Net margin
-101.3%
CDMO's gross profit has dropped by 66% year-on-year but it is up by 22% since the previous quarter
Avid Bioservices's gross margin has plunged by 64% YoY but it has increased by 21% from the previous quarter
CDMO's revenue is down by 5% year-on-year
CDMO's net income is down by 2.4% since the previous quarter
Growth
What is Avid Bioservices's growth rate over time
Valuation
What is Avid Bioservices stock price valuation
P/E
N/A
P/B
11.07
P/S
4.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.79
The company's EPS fell by 2.2% QoQ
CDMO's price to book (P/B) is 88% more than its last 4 quarters average of 5.9 and 2.5% more than its 5-year quarterly average of 10.8
Avid Bioservices's equity has shrunk by 69% YoY and by 3.7% QoQ
CDMO's P/S is 41% below its 5-year quarterly average of 7.7 but 30% above its last 4 quarters average of 3.5
CDMO's revenue is down by 5% year-on-year
Efficiency
How efficient is Avid Bioservices business performance
CDMO's return on equity is down by 30% since the previous quarter
The return on assets has declined by 10% since the previous quarter
Avid Bioservices's return on invested capital has decreased by 3.6% QoQ
The company's return on sales fell by 3.7% QoQ
Dividends
What is CDMO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CDMO.
Financial health
How did Avid Bioservices financials performed over time
The total assets is 21% greater than the total liabilities
The total assets has declined by 24% year-on-year
The total liabilities has increased by 9% year-on-year
Avid Bioservices's equity has shrunk by 69% YoY and by 3.7% QoQ
The company's debt rose by 9% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.